Next Article in Journal
Hippo Pathway in Cancer, towards the Realization of Hippo-Targeted Therapy
Previous Article in Journal
Involving the microRNA Targetome in Esophageal-Cancer Development and Behavior
Article Menu

Export Article

Open AccessArticle
Cancers 2018, 10(10), 382; https://doi.org/10.3390/cancers10100382

Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression

1
Department of Biology, Rio Piedras Campus, University of Puerto Rico, San Juan, PR 00931, USA
2
Department of Biochemistry, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, USA
3
Comprehensive Cancer Center, University of Puerto Rico, San Juan, PR 00935, USA
4
Department of Physiology, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, USA
5
Department of Pathology and Laboratory Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, USA
6
Anatomic Pathology Laboratory, Puerto Rico Medical Services Administration, San Juan, PR 00936, USA
*
Author to whom correspondence should be addressed.
Received: 9 August 2018 / Revised: 3 October 2018 / Accepted: 8 October 2018 / Published: 12 October 2018
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
Full-Text   |   PDF [2364 KB, uploaded 12 October 2018]   |  

Abstract

Glioblastoma (GBM) is the most common and aggressive of all brain tumors, with a median survival of only 14 months after initial diagnosis. Novel therapeutic approaches are an unmet need for GBM treatment. MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. Several dysregulated miRNAs have been identified in all cancer types including GBM. In this study, we aimed to uncover the role of miR-143 in GBM cell lines, patient samples, and mouse models. Quantitative real-time RT-PCR of RNA extracted from formalin-fixed paraffin-embedded (FFPE) samples showed that the relative expression of miR-143 was higher in GBM patients compared to control individuals. Transient transfection of GBM cells with a miR-143 oligonucleotide inhibitor (miR-143-inh) resulted in reduced cell proliferation, increased apoptosis, and cell cycle arrest. SLC30A8, a glucose metabolism-related protein, was identified as a direct target of miR-143 in GBM cells. Moreover, multiple injections of GBM tumor-bearing mice with a miR-143-inh-liposomal formulation significantly reduced tumor growth compared to control mice. The reduced in vitro cell growth and in vivo tumor growth following miRNA-143 inhibition suggests that miR-143 is a potential therapeutic target for GBM therapy. View Full-Text
Keywords: glioblastoma; microRNAs; mouse model; cell proliferation glioblastoma; microRNAs; mouse model; cell proliferation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Lozada-Delgado, E.L.; Grafals-Ruiz, N.; Miranda-Román, M.A.; Santana-Rivera, Y.; Valiyeva, F.; Rivera-Díaz, M.; Marcos-Martínez, M.J.; Vivas-Mejía, P.E. Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression. Cancers 2018, 10, 382.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top